View Item 

Show simple item record

Profibrotic agents for venous malformations?

dc.contributor.authorRittié, L.en_US
dc.date.accessioned2014-09-03T16:52:22Z
dc.date.availableWITHHELD_12_MONTHSen_US
dc.date.available2014-09-03T16:52:22Z
dc.date.issued2014-08en_US
dc.identifier.citationRittié, L. (2014). "Profibrotic agents for venous malformations?." British Journal of Dermatology (2): 209-210.en_US
dc.identifier.issn0007-0963en_US
dc.identifier.issn1365-2133en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/108378
dc.publisherWiley Periodicals, Inc.en_US
dc.titleProfibrotic agents for venous malformations?en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelDermatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/108378/1/bjd13164.pdf
dc.identifier.doi10.1111/bjd.13164en_US
dc.identifier.sourceBritish Journal of Dermatologyen_US
dc.identifier.citedreferenceJin Y, Lin X, Li W et al. Sclerotherapy after embolization of draining vein: a safe treatment method for venous malformations. J Vasc Surg 2008; 47: 1292 – 9.en_US
dc.identifier.citedreferenceYang Y, Sun M, Ma Q et al. Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations. J Vasc Surg 2011; 53: 150 – 5.en_US
dc.identifier.citedreferenceMarler JJ, Mulliken JB. Vascular anomalies: classification, diagnosis, and natural history. Facial Plast Surg Clin North Am 2001; 9: 495 – 504.en_US
dc.identifier.citedreferenceNorth PE, Mihm MC Jr. Histopathological diagnosis of infantile hemangiomas and vascular malformations. Facial Plast Surg Clin North Am 2001; 9: 505 – 24.en_US
dc.identifier.citedreferenceHill RA, Pho RW, Kumar VP. Resection of vascular malformations. J Hand Surg Br 1993; 18: 17 – 21.en_US
dc.identifier.citedreferenceRen JG, Chen G, Zhu JY et al. Downregulation of the transforming growth factor‐β/connective tissue growth factor 2 signalling pathway in venous malformations: its target potential for sclerotherapy. Br J Dermatol 2014; 171: 242 – 51.en_US
dc.identifier.citedreferencePerbal B. CCN proteins: multifunctional signalling regulators. Lancet 2004; 363: 62 – 4.en_US
dc.identifier.citedreferenceJun JI, Lau LF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 2011; 10: 945 – 63.en_US
dc.identifier.citedreferenceHall‐Glenn F, De Young RA, Huang BL et al. CCN2/connective tissue growth factor is essential for pericyte adhesion and endothelial basement membrane formation during angiogenesis. PLOS ONE 2012; 7: e30562.en_US
dc.identifier.citedreferenceLipson KE, Wong C, Teng Y, Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair 2012; 5 ( Suppl. 1 ): S24.en_US
dc.identifier.citedreferenceSpence J, Krings T, TerBrugge KG, Agid R. Percutaneous treatment of facial venous malformations: a matched comparison of alcohol and bleomycin sclerotherapy. Head Neck 2011; 33: 125 – 30.en_US
dc.identifier.citedreferenceGarzon MC, Huang JT, Enjolras O, Frieden IJ. Vascular malformations: Part I. J Am Acad Dermatol 2007; 56: 353 – 70.en_US
dc.identifier.citedreferenceLegiehn GM, Heran MK. Venous malformations: classification, development, diagnosis, and interventional radiologic management. Radiol Clin North Am 2008; 46: 545 – 97, vi.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bjd13164.pdf
Size:
45.53KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.